Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL

Conclusions
Elderly men benefited from treatment with enzalutamide in terms of OS and rPFS. Enzalutamide was well tolerated in the elderly subgroup and those aged <75 years. Age and enzalutamide treatment were associated with a higher incidence of falls.

Clinical trial identifier
NCT01212991, ClinicalTrials.gov.

Source: Annals of Oncology - January 22, 2016 Category: Cancer & Oncology Authors: Graff, J. N., Baciarello, G., Armstrong, A. J., Higano, C. S., Iversen, P., Flaig, T. W., Forer, D., Parli, T., Phung, D., Tombal, B., Beer, T. M., Sternberg, C. N. Tags: urogenital tumors Source Type: research